# Randomized Study of Obicetrapib in Combination With Ezetimibe

Study · id `cardio:ct-nct04770389` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04770389](<https://clinicaltrials.gov/study/NCT04770389>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04770389

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 112 participants.

## Technical summary

Registry record NCT04770389. Randomized; quadruple masking; primary purpose treatment. Start 2021-02-23 (actual); primary completion 2021-05-07 (actual). Results posted on 2024-04-24.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 112 participants (enrolled count; ClinicalTrials.gov record NCT04770389, source copy `cardio:ctgov-nct04770389-2024-04-24`, retrieved 2026-10-31)
- Started: 2021-02-23 (actual) (ClinicalTrials.gov record NCT04770389, source copy `cardio:ctgov-nct04770389-2024-04-24`, retrieved 2026-10-31)
- Primary completion: 2021-05-07 (actual) (ClinicalTrials.gov record NCT04770389, source copy `cardio:ctgov-nct04770389-2024-04-24`, retrieved 2026-10-31)
- Completion: 2021-06-30 (actual) (ClinicalTrials.gov record NCT04770389, source copy `cardio:ctgov-nct04770389-2024-04-24`, retrieved 2026-10-31)
- Results first posted: 2024-04-24 (ClinicalTrials.gov record NCT04770389, source copy `cardio:ctgov-nct04770389-2024-04-24`, retrieved 2026-10-31)
- Countries: United States; Netherlands (ClinicalTrials.gov record NCT04770389, source copy `cardio:ctgov-nct04770389-2024-04-24`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04770389-2024-04-24`, retrieved 2026-10-31)

## The registry's words

- Brief title: Randomized Study of Obicetrapib in Combination With Ezetimibe
- Acronym: OCEAN
- Condition: Dyslipidemias
- Condition: High Cholesterol
- Condition: Hypercholesterolemia
- Intervention (Drug): Obicetrapib 5mg
- Intervention (Drug): Ezetimibe 10mg
- Intervention (Other): Placebo
- Lead sponsor: NewAmsterdam Pharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: NewAmsterdam Pharma (`cardio:org-newamsterdam-pharma`)

## Provenance

Content hash: d85f2e646d5fac8f7d0e2b1880f9ebf54abde2afd54ce6d8fb3ee86786ca9f67
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
